Radiopharm Theranostics Limited (ASX:RAD), Telix Pharmaceuticals Limited (ASX:TLX) and Clarity Pharmaceuticals Limited (ASX:CU6) provide exposure to different stages of the radiopharmaceutical sector. Radiopharm remains a clinical-stage developer, Telix has established commercial imaging revenue, while Clarity is progressing late-stage diagnostic and therapeutic programmes based on its copper theranostics platform.

Their financial profiles are equally different. Radiopharm continues to depend on external capital, Telix is generating profit and Operating Cash Flow from commercial products, while Clarity remains pre-commercial but holds a sizeable cash position to support clinical development.

Radiopharma Outlook

Radiopharmaceutical companies combine Drug Development with specialised Manufacturing and isotope Supply requirements. Commercial success therefore depends not only on clinical and regulatory outcomes but also on manufacturing capacity, distribution infrastructure and reimbursement.

For ASX-listed companies in the sector, cash resources remain especially important. Clinical-stage businesses can consume significant Capital before product Revenue begins, while commercial companies need to balance pipeline Investment against profitability.

Radiopharm Theranostics Limited (ASX:RAD)

Company Profile

Radiopharm Theranostics is developing a portfolio of diagnostic and therapeutic radiopharmaceuticals across several cancer indications.

Its pipeline includes RAD 101 for brain-metastasis imaging alongside earlier-stage therapeutic and diagnostic programmes using different targeting technologies and radioactive isotopes.

Financial Position

Radiopharm reported approximately AUD 4.1 million of cash at 30 June 2026.

Net operating cash outflow for the June quarter was approximately AUD 14.97 million, with research, development and employee costs accounting for most of the expenditure.

The company subsequently undertook additional capital raising activity and also received an AUD 5.9 million Research and Development tax incentive refund.

These funding initiatives provide additional development capacity as Radiopharm advances its clinical programmes.

Outlook and Risks

Radiopharm remains focused on progressing RAD 101 toward a potential pivotal development programme while continuing work across its broader pipeline.

The main financial consideration remains funding. Clinical development expenditure is substantial relative to existing cash resources, meaning continued access to capital may remain necessary.

Regulatory requirements and future trial design will also influence the amount of funding required.

Telix Pharmaceuticals Limited (ASX:TLX)

Company Profile

Telix Pharmaceuticals develops and commercialises radiopharmaceutical products across diagnostic imaging and therapeutic applications.

Its commercial portfolio includes prostate cancer imaging products, while additional diagnostic and therapeutic candidates remain under regulatory review or clinical development.

Telix also operates a manufacturing division supporting its own portfolio and third-party customers.

1H 2026 Financial Performance

For the six months ended 30 June 2026, Telix reported revenue of USD 477 million.

Gross profit reached USD 260 million, representing a gross Margin of 55%.

Adjusted EBITDA was USD 52 million, while net profit after tax reached USD 38 million.

Operating cash flow was USD 23 million.

Telix ended the period with USD 252 million of cash.

The Precision Medicine division remained the main Earnings contributor, while the Manufacturing Solutions operation continued to require investment.

2026 Outlook

Telix expects full-year 2026 revenue and other income to exceed USD 1 billion, with revenue tracking toward the upper end of its previously indicated range.

Research and development expenditure is expected to remain substantial as the company progresses additional diagnostic and therapeutic programmes.

The key financial consideration is whether expanding commercial revenue can continue supporting increased pipeline and manufacturing investment.

Risks

Telix remains exposed to regulatory timing across products under review and continues to invest heavily in development and manufacturing infrastructure.

The Business also remains concentrated around prostate cancer imaging for a significant portion of commercial revenue.

Pipeline expansion could diversify the revenue base over time, but regulatory approval and commercial adoption are not assured.

Clarity Pharmaceuticals Limited (ASX:CU6)

Company Profile

Clarity Pharmaceuticals develops radiopharmaceuticals using its Targeted Copper Theranostics platform.

The company uses copper-64 for diagnostic imaging and copper-67 for therapy, with programmes spanning prostate cancer and neuroendocrine tumours.

Its lead diagnostic studies are progressing through late-stage development while therapeutic programmes remain under clinical evaluation.

FY2026 Financial Performance

Clarity reported FY2026 income of AUD 8.0 million.

The company recorded a net loss of AUD 107.2 million as research and development expenditure increased to AUD 91.1 million.

Cash and Liquid assets stood at AUD 178.3 million at 30 June 2026.

Clarity does not currently generate commercial product sales, meaning its financial profile continues to be driven mainly by clinical development expenditure.

Outlook and Risks

Clarity is focused on completing late-stage diagnostic studies and progressing its therapeutic pipeline.

Its cash position provides substantial development capacity, although the current level of research expenditure means cash consumption remains high.

Future financial requirements will depend on clinical results, regulatory pathways and the scope of subsequent development programmes.

Risks to Watch

Radiopharm faces the most immediate funding pressure because development expenditure remains high relative to its available cash.

Telix has the most established commercial and financial position, although continued pipeline investment and regulatory execution remain important.

Clarity has a sizeable cash balance but is also spending heavily on late-stage development without commercial product revenue.

Across all three companies, regulatory timelines, manufacturing requirements and access to isotope supply can influence both costs and commercial progress.

What Investors May Watch Through the Rest of 2026

For Radiopharm, investors may monitor regulatory discussions around RAD 101, clinical progress and the company's funding position.

For Telix, commercial revenue growth, profitability and progress across products under regulatory review may remain central.

For Clarity, attention may remain on late-stage trial progress, research expenditure and the pace at which its cash balance is deployed.

The three companies therefore represent different stages of radiopharmaceutical development: Radiopharm is progressing an earlier clinical portfolio, Telix has reached commercial scale, and Clarity is investing heavily in late-stage clinical programmes.